<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445794</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-002</org_study_id>
    <nct_id>NCT02445794</nct_id>
  </id_info>
  <brief_title>A First in Human Study of RT001 in Patients With Friedreich's Ataxia</brief_title>
  <official_title>A Randomized, Double-blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retrotope, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retrotope, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of&#xD;
      RT001 in patients with Friedreich's ataxia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study RT001-002 is a randomized, double-blind, controlled, ascending dose study to evaluate&#xD;
      the safety, tolerability, pharmacokinetic, disease state, and exploratory endpoints in&#xD;
      patients with Friedreich's ataxia after oral administration. The study includes 2 dose levels&#xD;
      of RT001.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area Under the Concentration-time Curve After a Single Dose</measure>
    <time_frame>24 hours</time_frame>
    <description>AUC 0-24 hours post-dose (Hours -1.0 to -0.5 (pre-breakfast, pre-dose), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 2: 24 hours following dosing on Day 1 (± 30 min; pre-breakfast, pre-dose) was measured for the low and high dose cohorts after a single dose of RT001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum Observed Plasma Concentration After a Single Dose</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma levels were measured for the following time points: Day 1: Hours -1.0 to -0.5 (pre-breakfast, pre-dose), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 2: 24 hours following dosing on Day 1 (± 30 min; pre-breakfast, pre-dose) PK curves were constructed from these data and CMax measured on the curves for the low and high dose cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to Reach Maximum Plasma Concentration After a Single Dose</measure>
    <time_frame>24 hours</time_frame>
    <description>TMax measured for the low and high dose cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum Observed Plasma Concentration After Final Dose on Day 28</measure>
    <time_frame>Day 28-Day 31 (3 days)</time_frame>
    <description>After 28 days of dosing, the final dose of RT001 was administered, and PK samples were obtained at the following timepoints (all timepoints refer to final dose on Day 28):&#xD;
Day 28: Hours -1.0 to -0.5 (pre-breakfast, pre-dose on Day 28), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 29: Hours 24 (± 30 min; pre-breakfast) and 32 (± 30 min) hours following final dose on Day 28 Day 30: 48 hours following final dose on Day 28 (± 30 min; pre-breakfast) Day 31: 72 hours following final dose on Day 28 (± 30 min; pre-breakfast) PK curves were constructed, and CMax at 28 days was determined from these curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Terminal Half-life Estimation After Final Dose on Day 28</measure>
    <time_frame>Day 28-Day 31 (3 days)</time_frame>
    <description>After 28 days of dosing, the final dose of RT001 was administered, and PK samples were obtained at the following timepoints (all timepoints refer to final dose on Day 28):&#xD;
Day 28: Hours -1.0 to -0.5 (pre-breakfast, pre-dose on Day 28), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 29: Hours 24 (± 30 min; pre-breakfast) and 32 (± 30 min) hours following final dose on Day 28 Day 30: 48 hours following final dose on Day 28 (± 30 min; pre-breakfast) Day 31: 72 hours following final dose on Day 28 (± 30 min; pre-breakfast) PK curves were constructed, and T1/2 at 28 days was determined from these curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 28 Days in the Timed 25 Foot Walk (T25FW)</measure>
    <time_frame>28 days</time_frame>
    <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk.&#xD;
T25FW was measured at baseline and at 28 days. These data were compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 28 Days in the Friedreich Ataxia Rating Scale (FARS) - Neurological Score (Minimum Score 0, Maximum Score 125, Lower is Better)</measure>
    <time_frame>28 days</time_frame>
    <description>The FARS-neurological rating scale specifically developed and validated for Friedreich's Ataxia. The FARS-Neurological included evaluations of the neurological signs that specifically reflect neural substrates affected in patients with FA. Based on a neurological examination bulbar (11 points), upper limb coordination (36 points), lower limb coordination (16 points), peripheral nervous system (26 points), and upright stability (36 points) functions were assessed for individual sub-scores (11, 36, 16, 26, and 36) with a maximum score of 125 (Friedreich's Ataxia Study Group, Subramony et al., 2005, Lynch et al., 2006). FARS-Neurologic examinations were conducted by a qualified physician or health professional trained in the use of the FARS format. A lower score is better. The minimum score is 0, the maximum score is 125.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 28 Days in Peak Workload for the Treated Population vs. the Comparator Population</measure>
    <time_frame>28 days</time_frame>
    <description>Peak workload was measured using cardiopulmonary exercise testing at baseline and after 28 days of treatment. The results of treatment were compared to baseline examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>RT001, oral, 1.8 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001, oral, 1.8 g QD for 28 days or matching comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT001, oral, 9 g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001, oral, 4.5 g BID for 28 days or matching comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose cohort</intervention_name>
    <description>RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
    <arm_group_label>RT001, oral, 1.8 g/day</arm_group_label>
    <arm_group_label>RT001, oral, 9 g/day</arm_group_label>
    <other_name>RT001 1.8 g/d (2 capsule per day)</other_name>
    <other_name>RT001 comparator 1.8 g/d (2 capsule per day)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose cohort</intervention_name>
    <description>RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
    <arm_group_label>RT001, oral, 1.8 g/day</arm_group_label>
    <arm_group_label>RT001, oral, 9 g/day</arm_group_label>
    <other_name>RT001 9.0 g/d (9 capsule per day)</other_name>
    <other_name>RT001 comparator 9.0 g/d (9 capsule per day)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 18 to 50 years of age&#xD;
&#xD;
          2. Medical history consistent with the symptoms of FRDA at ≤ 25 years of age&#xD;
&#xD;
          3. Homozygous for GAA repeat expansions in the Frataxin gene in the affected range for&#xD;
             FRDA&#xD;
&#xD;
          4. FARS-Neurological score of 20-90 points&#xD;
&#xD;
          5. Ambulatory (with or without assistive device) and capable of performing&#xD;
             assessments/evaluations&#xD;
&#xD;
          6. Body Mass Index ≤ 29.9 kg/m2&#xD;
&#xD;
          7. Agrees to dietary restrictions and agrees to receive calls from a dietary coach&#xD;
&#xD;
          8. Signed the informed consent form prior to entry into the study&#xD;
&#xD;
          9. Agrees to spend the required number of overnight clinic days&#xD;
&#xD;
         10. Able to provide the necessary repeated blood samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received treatment with other experimental therapies within the last 30 days prior to&#xD;
             the first dose&#xD;
&#xD;
          2. Known point mutation in the FXN gene&#xD;
&#xD;
          3. History of malignancies (other than basal cell carcinomas)&#xD;
&#xD;
          4. Impaired renal function at screening&#xD;
&#xD;
          5. Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values &gt; 2 x&#xD;
             upper limit of normal (ULN) at screening&#xD;
&#xD;
          6. Known hepatitis B surface antigen (HBsAg)-positive, or known or suspected active&#xD;
             hepatitis C infection, or is known to be human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          7. Female who is breastfeeding or has a positive pregnancy test&#xD;
&#xD;
          8. Male participant or female participant of child bearing potential, who is sexually&#xD;
             active and unwilling/unable to use a medically acceptable and effective double barrier&#xD;
             birth control method throughout the study&#xD;
&#xD;
          9. Unwilling or unable to comply with the requirements of the protocol&#xD;
&#xD;
         10. Clinically significant cardiac abnormalities at screening that, in the opinion of the&#xD;
             Investigator, would make the patient unsuitable for enrollment&#xD;
&#xD;
         11. Diabetes mellitus (Type 1 or 2)&#xD;
&#xD;
         12. Suicidal ideation as determined by the Columbia-Suicide Severity Rating Scale&#xD;
&#xD;
         13. History, within the last 2 years, of alcohol abuse, significant mental illness, or&#xD;
             physical opioid dependence&#xD;
&#xD;
         14. Cannot adhere to the dietary guidance required to be followed by the protocol&#xD;
&#xD;
         15. Cannot take the medication due to impairment in swallowing capsules&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Curtis Scribner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Retrotope, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theresa Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USF Ataxia Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>November 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2020</results_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 - RT001 (1.8 g/Day)</title>
          <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 - Comparator</title>
          <description>RT001 comparator, oral, 2 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2 - RT001 (9 g/Day)</title>
          <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 - Comparator</title>
          <description>RT001 comparator, oral, 10 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 - RT001</title>
          <description>RT001 - 2 capsules/day (1.8 g/day)</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 - Comparator</title>
          <description>RT001 comparator - 2 capsules/day</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2 - RT001</title>
          <description>RT001 - 10 capsules/day (9 g/day)</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 - Comparator</title>
          <description>RT001 comparator - 10 capsules/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="7.61"/>
                    <measurement group_id="B2" value="45.3" spread="2.08"/>
                    <measurement group_id="B3" value="28.6" spread="7.46"/>
                    <measurement group_id="B4" value="26.3" spread="4.16"/>
                    <measurement group_id="B5" value="34.3" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.82" spread="3.857"/>
                    <measurement group_id="B2" value="26.17" spread="2.798"/>
                    <measurement group_id="B3" value="21.63" spread="3.096"/>
                    <measurement group_id="B4" value="24.63" spread="7.931"/>
                    <measurement group_id="B5" value="23.47" spread="4.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - RT001 (1.8 g/Day)</title>
            <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Comparator</title>
            <description>RT001 comparator, oral, 2 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - RT001 (9 g/Day)</title>
            <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Comparator</title>
            <description>RT001 comparator, oral, 10 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Area Under the Concentration-time Curve After a Single Dose</title>
        <description>AUC 0-24 hours post-dose (Hours -1.0 to -0.5 (pre-breakfast, pre-dose), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 2: 24 hours following dosing on Day 1 (± 30 min; pre-breakfast, pre-dose) was measured for the low and high dose cohorts after a single dose of RT001</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RT001, Oral, 1.8 g/Day</title>
            <description>RT001, oral, 1.8 g QD for 28 days or matching comparator&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
          <group group_id="O2">
            <title>RT001, Oral, 9 g/Day</title>
            <description>RT001, oral, 4.5 g BID for 28 days or matching comparator&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Area Under the Concentration-time Curve After a Single Dose</title>
          <description>AUC 0-24 hours post-dose (Hours -1.0 to -0.5 (pre-breakfast, pre-dose), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 2: 24 hours following dosing on Day 1 (± 30 min; pre-breakfast, pre-dose) was measured for the low and high dose cohorts after a single dose of RT001</description>
          <units>ug*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524" spread="86"/>
                    <measurement group_id="O2" value="915" spread="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Maximum Observed Plasma Concentration After a Single Dose</title>
        <description>Plasma levels were measured for the following time points: Day 1: Hours -1.0 to -0.5 (pre-breakfast, pre-dose), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 2: 24 hours following dosing on Day 1 (± 30 min; pre-breakfast, pre-dose) PK curves were constructed from these data and CMax measured on the curves for the low and high dose cohorts</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - RT001 (1.8 g/Day)</title>
            <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - RT001 (9 g/Day)</title>
            <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Maximum Observed Plasma Concentration After a Single Dose</title>
          <description>Plasma levels were measured for the following time points: Day 1: Hours -1.0 to -0.5 (pre-breakfast, pre-dose), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 2: 24 hours following dosing on Day 1 (± 30 min; pre-breakfast, pre-dose) PK curves were constructed from these data and CMax measured on the curves for the low and high dose cohorts</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="9.8"/>
                    <measurement group_id="O2" value="58.6" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Time to Reach Maximum Plasma Concentration After a Single Dose</title>
        <description>TMax measured for the low and high dose cohorts</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - RT001 (1.8 g/Day)</title>
            <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - RT001 (9 g/Day)</title>
            <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Time to Reach Maximum Plasma Concentration After a Single Dose</title>
          <description>TMax measured for the low and high dose cohorts</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="0"/>
                    <measurement group_id="O2" value="8.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Maximum Observed Plasma Concentration After Final Dose on Day 28</title>
        <description>After 28 days of dosing, the final dose of RT001 was administered, and PK samples were obtained at the following timepoints (all timepoints refer to final dose on Day 28):&#xD;
Day 28: Hours -1.0 to -0.5 (pre-breakfast, pre-dose on Day 28), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 29: Hours 24 (± 30 min; pre-breakfast) and 32 (± 30 min) hours following final dose on Day 28 Day 30: 48 hours following final dose on Day 28 (± 30 min; pre-breakfast) Day 31: 72 hours following final dose on Day 28 (± 30 min; pre-breakfast) PK curves were constructed, and CMax at 28 days was determined from these curves</description>
        <time_frame>Day 28-Day 31 (3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - RT001 (1.8 g/Day)</title>
            <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - RT001 (9 g/Day)</title>
            <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Maximum Observed Plasma Concentration After Final Dose on Day 28</title>
          <description>After 28 days of dosing, the final dose of RT001 was administered, and PK samples were obtained at the following timepoints (all timepoints refer to final dose on Day 28):&#xD;
Day 28: Hours -1.0 to -0.5 (pre-breakfast, pre-dose on Day 28), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 29: Hours 24 (± 30 min; pre-breakfast) and 32 (± 30 min) hours following final dose on Day 28 Day 30: 48 hours following final dose on Day 28 (± 30 min; pre-breakfast) Day 31: 72 hours following final dose on Day 28 (± 30 min; pre-breakfast) PK curves were constructed, and CMax at 28 days was determined from these curves</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="44.6"/>
                    <measurement group_id="O2" value="359.9" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Terminal Half-life Estimation After Final Dose on Day 28</title>
        <description>After 28 days of dosing, the final dose of RT001 was administered, and PK samples were obtained at the following timepoints (all timepoints refer to final dose on Day 28):&#xD;
Day 28: Hours -1.0 to -0.5 (pre-breakfast, pre-dose on Day 28), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 29: Hours 24 (± 30 min; pre-breakfast) and 32 (± 30 min) hours following final dose on Day 28 Day 30: 48 hours following final dose on Day 28 (± 30 min; pre-breakfast) Day 31: 72 hours following final dose on Day 28 (± 30 min; pre-breakfast) PK curves were constructed, and T1/2 at 28 days was determined from these curves</description>
        <time_frame>Day 28-Day 31 (3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - RT001 (1.8 g/Day)</title>
            <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - RT001 (9 g/Day)</title>
            <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Terminal Half-life Estimation After Final Dose on Day 28</title>
          <description>After 28 days of dosing, the final dose of RT001 was administered, and PK samples were obtained at the following timepoints (all timepoints refer to final dose on Day 28):&#xD;
Day 28: Hours -1.0 to -0.5 (pre-breakfast, pre-dose on Day 28), 0.5 (± 5 min), 1 (± 5 min), 1.5 (± 5 min), 2 (± 10 min), 4 (± 10 min) (pre-lunch), 6 (± 10 min), 8 (± 10 min), 12 (± 10 min), and 16 (± 30 min) Day 29: Hours 24 (± 30 min; pre-breakfast) and 32 (± 30 min) hours following final dose on Day 28 Day 30: 48 hours following final dose on Day 28 (± 30 min; pre-breakfast) Day 31: 72 hours following final dose on Day 28 (± 30 min; pre-breakfast) PK curves were constructed, and T1/2 at 28 days was determined from these curves</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="9.77"/>
                    <measurement group_id="O2" value="30.3" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 28 Days in the Timed 25 Foot Walk (T25FW)</title>
        <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk.&#xD;
T25FW was measured at baseline and at 28 days. These data were compared.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - RT001 (1.8 g/Day)</title>
            <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Comparator</title>
            <description>RT001 comparator, oral, 2 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - RT001 (9 g/Day)</title>
            <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Comparator</title>
            <description>RT001 comparator, oral, 10 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 28 Days in the Timed 25 Foot Walk (T25FW)</title>
          <description>The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk.&#xD;
T25FW was measured at baseline and at 28 days. These data were compared.</description>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".503" spread="3.7751"/>
                    <measurement group_id="O2" value="-1.87" spread="1.1653"/>
                    <measurement group_id="O3" value="-7.475" spread="28.6458"/>
                    <measurement group_id="O4" value=".608" spread="2.4182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 28 Days in the Friedreich Ataxia Rating Scale (FARS) - Neurological Score (Minimum Score 0, Maximum Score 125, Lower is Better)</title>
        <description>The FARS-neurological rating scale specifically developed and validated for Friedreich's Ataxia. The FARS-Neurological included evaluations of the neurological signs that specifically reflect neural substrates affected in patients with FA. Based on a neurological examination bulbar (11 points), upper limb coordination (36 points), lower limb coordination (16 points), peripheral nervous system (26 points), and upright stability (36 points) functions were assessed for individual sub-scores (11, 36, 16, 26, and 36) with a maximum score of 125 (Friedreich's Ataxia Study Group, Subramony et al., 2005, Lynch et al., 2006). FARS-Neurologic examinations were conducted by a qualified physician or health professional trained in the use of the FARS format. A lower score is better. The minimum score is 0, the maximum score is 125.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - RT001 (1.8 g/Day)</title>
            <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Comparator</title>
            <description>RT001 comparator, oral, 2 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - RT001 (9 g/Day)</title>
            <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Comparator</title>
            <description>RT001 comparator, oral, 10 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 28 Days in the Friedreich Ataxia Rating Scale (FARS) - Neurological Score (Minimum Score 0, Maximum Score 125, Lower is Better)</title>
          <description>The FARS-neurological rating scale specifically developed and validated for Friedreich's Ataxia. The FARS-Neurological included evaluations of the neurological signs that specifically reflect neural substrates affected in patients with FA. Based on a neurological examination bulbar (11 points), upper limb coordination (36 points), lower limb coordination (16 points), peripheral nervous system (26 points), and upright stability (36 points) functions were assessed for individual sub-scores (11, 36, 16, 26, and 36) with a maximum score of 125 (Friedreich's Ataxia Study Group, Subramony et al., 2005, Lynch et al., 2006). FARS-Neurologic examinations were conducted by a qualified physician or health professional trained in the use of the FARS format. A lower score is better. The minimum score is 0, the maximum score is 125.</description>
          <units>units on a scale maximum 125</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.22" spread="2.796"/>
                    <measurement group_id="O2" value="-6.47" spread="4.768"/>
                    <measurement group_id="O3" value="-3.3" spread="2.080"/>
                    <measurement group_id="O4" value="-2" spread="3.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 28 Days in Peak Workload for the Treated Population vs. the Comparator Population</title>
        <description>Peak workload was measured using cardiopulmonary exercise testing at baseline and after 28 days of treatment. The results of treatment were compared to baseline examination.</description>
        <time_frame>28 days</time_frame>
        <population>Subjects unable to start or complete the test were excluded from analysis. Treatment and comparator cohorts were pooled to allow for statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RT001</title>
            <description>RT001, oral (pooled 1.8 g/d + 9.0 g/d)&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Comparator</title>
            <description>RT001 comparator, oral&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 28 Days in Peak Workload for the Treated Population vs. the Comparator Population</title>
          <description>Peak workload was measured using cardiopulmonary exercise testing at baseline and after 28 days of treatment. The results of treatment were compared to baseline examination.</description>
          <population>Subjects unable to start or complete the test were excluded from analysis. Treatment and comparator cohorts were pooled to allow for statistical analysis.</population>
          <units>watts/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".08" lower_limit="-.1" upper_limit=".34"/>
                    <measurement group_id="O2" value="-.08" lower_limit="-.3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 - RT001 (1.8 g/Day)</title>
          <description>RT001, oral, 2 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 - Comparator</title>
          <description>RT001 comparator, oral, 2 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 - RT001 (9 g/Day)</title>
          <description>RT001, oral, 10 capsules/day&#xD;
RT001: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 - Comparator</title>
          <description>RT001 comparator, oral, 10 capsules/day&#xD;
RT001 comparator: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Steatorrhea requiring overnight hospitalization</sub_title>
                <description>The subject developed severe steatorrhea after a single dose of RT001. This required overnight hospitalization. The condition resolved after within 24 hours after drug discontinuation.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <description>Most of the TEAEs were mild gastrointestinal distress due to the fat content of the study drug (both active and the comparator.) They were self-limited.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>facial fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frederic Heerinckx/VP Clinical Operations</name_or_title>
      <organization>Retrotope, Inc</organization>
      <phone>650-437-0700 ext 109</phone>
      <email>frederic@retrotope.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

